All In Biotech

Drug Trial Radar · NCT00244842

Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis

A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients

Last checked: Nov 19, 2026Latest source record: Mar 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 451 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

451

Actual

Start

Dec 2004

Primary completion

Oct 2005

Study completion Oct 2005

Sponsor

Lead sponsor
Aurinia Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Oct 27, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo.

Conditions

  • Psoriasis

Interventions

  • voclosporinDrug

    voclosporin 0.2, 0.3, or 0.4 mg/kg po BID

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Achieving a PASI-75 at 12 Weeks at Each of the 3 Dose Levels of Voclosporin.Time frame: Twelve Weeks

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Isotechnika Investigational Site

    Calgary, Alberta, Canada

  • Isotechnika Investigational Site'

    Edmonton, Alberta, Canada

  • Isotechnika Investigational Site

    Edmonton, Alberta, Canada

  • Isotechnika Investigational Site

    Vancouver, British Columbia, Canada

  • Isotechnika Investigational Site

    Vancouver, British Columbia, Canada

  • Isotechnika Investigational Site

    Victoria, British Columbia, Canada

  • Isotechnika Investigational Site

    Winnipeg, Manitoba, Canada

  • Isotechnika Investigational Site

    Moncton, New Brunswick, Canada

  • Isotechnika Investigational Site

    St. John's, Newfoundland and Labrador, Canada

  • Isotechnika Investigational Site

    St. John's, Newfoundland and Labrador, Canada

  • Isotechnika Investigational Site

    Halifax, Nova Scotia, Canada

  • Isotechnika Investigational Site

    Hamilton, Ontario, Canada

  • Isotechnika Investigational Site

    London, Ontario, Canada

  • Isotechnika Investigational Site

    London, Ontario, Canada

  • Isotechnika Investigational Site

    Maple, Ontario, Canada

  • Isotechnika Investigational Site

    Markham, Ontario, Canada

  • Isotechnika Investigational Site

    Newmarket, Ontario, Canada

  • Isotechnika Investigational Site

    North Bay, Ontario, Canada

  • Isotechnika Investigational Site

    North Bay, Ontario, Canada

  • Isotechnika Investigational Site

    Oakville, Ontario, Canada

  • Isotechnika Investigational Site

    Oshawa, Ontario, Canada

  • Isotechnika Investigational Site

    Toronto, Ontario, Canada

  • Isotechnika Investigational Site

    Waterloo, Ontario, Canada

  • Isotechnika Investigational Site

    Windsor, Ontario, Canada

  • Isotechnika Investigational Site

    Windsor, Ontario, Canada

  • Isotechnika Investigational Site

    Laval, Quebec, Canada

  • Isotechnika Investigational Site

    Montreal, Quebec, Canada

  • Isotechnika Investigational Site

    Montreal, Quebec, Canada

  • Isotechnika Investigational Site

    Pointe-Claire, Quebec, Canada

  • Isotechnika Investigational Site

    Sherbrooke, Quebec, Canada

  • Isotechnika Investigational Site

    Ste. Foy, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.